Accepted for Publication: December 30, 2014.
Published Online: February 23, 2015. doi:10.1001/jamapediatrics.2014.3804.
Study concept and design: Gutfraind, Meyers.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: All authors.
Obtained funding: Galvani, Meyers.
Administrative, technical, or material support: Meyers.
Study supervision: Meyers.
Conflict of Interest Disclosures: None reported.
Funding/Support: This study was supported by Models of Infectious Disease Agent Study grant U01GM087719 from the National Institutes of General Medical Sciences (Drs Galvani and Meyers). Dr. Gutfraind is also supported through the Oak Ridge Institute for Science and Education Fellowship Program and a pilot grant from the University of Illinois at Chicago.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Previous Presentation: This paper was presented as a poster at the Conference on Evolution and Ecology of Infectious Diseases; May 23-24, 2012; Ann Arbor, Michigan.
Additional Contributions: Rosalind M. Eggo, PhD, University of Texas at Austin, and Ed Goldstein, PhD, Harvard University, provided guidance on interpreting the surveillance data. Marilyn Felkner, DrPH, and Lesley Brannan, MPH, Texas Department of State Health Services, provided guidance on RSV surveillance and palivizumab administration policies. The Centers for Disease Control and Prevention shared National Respiratory and Enteric Virus Surveillance System outbreak data on RSV. MedImmune provided information on palivizumab. Anonymous reviewers provided excellent suggestions for improving both clarity and rigor. No compensation was provided for these contributions.